SELLAS Life Sciences Group, Inc. (SLS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SLS Revenue Growth
SLS Revenue Analysis (2014–2025)
As of May 8, 2026, SELLAS Life Sciences Group, Inc. (SLS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, SLS's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $9.3 million in 2014.
When compared to Healthcare sector peers including ADMA (+11.0% YoY), NKTR (-43.9% YoY), and CLDX (-78.6% YoY). Compare SLS vs ADMA →
SLS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLSCurrent | $0 | - | - | - | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% |
SLS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-28,274,000 | - |
| 2024 | $0 | - | $0 | - | $-31,513,000 | - |
| 2023 | $0 | -100.0% | $0 | - | $-37,869,000 | - |
| 2022 | $1.0M | -86.8% | $900K | 90.0% | $-41,950,000 | -4195.0% |
| 2021 | $7.6M | +300.0% | $7.4M | 97.4% | $-25,294,000 | -332.8% |
| 2020 | $1.9M | - | $1.9M | 100.0% | $-16,982,000 | -893.8% |
| 2019 | $0 | - | $0 | - | $-20,041,000 | - |
| 2018 | $0 | - | $0 | - | $-31,589,000 | - |
| 2017 | $0 | - | $0 | - | $-15,714,000 | - |
| 2016 | $0 | - | $-3,000 | - | $-15,988,000 | - |
See SLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLS — Frequently Asked Questions
Quick answers to the most common questions about buying SLS stock.
Is SLS's revenue growth accelerating or slowing?
SLS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is SLS's long-term revenue growth rate?
SELLAS Life Sciences Group, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is SLS's revenue distributed by segment?
SLS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.